Apolipoprotein B-48 to triglyceride ratio is a novel and useful marker for detection of type III hyperlipidemia after antihyperlipidemic intervention

Miyako Yuasa-Kawase, Daisaku Masuda, Rika Kitazume-Taneike, Taiji Yamashita, Ryota Kawase, Hajime Nakaoka, Miwako Inagaki, Kazuhiro Nakatani, Kazumi Tsubakio-Yamamoto, Tohru Ohama, Yumiko Toyama-Nakagawa, Makoto Nishida, Masato Ishigami, Mieko Saito, Masaaki Eto, Akifumi Matsuyama, Issei Komuro, Shizuya Yamashita

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aim: Remnant lipoproteins are atherogenic and are accumulated in patients with type III hyperlipidemia (HL). Although type III HL is diagnosed by phenotyping apolipoprotein (apo) E, this procedure is time-consuming and inconvenient for routine clinical use. Clinical indices for screening type III HL in untreated HL patients have been proposed; however, in clinical settings, HL patients are promptly treated with lipid-lowering agents without diagnosing the underlying cause. We investigated whether existing clinical indices for screening type III HL as well as the apo B-48/triglyceride (TG) ratio, which was suggested to be related to the accumulation of small chylomicron (CM) remnants, are useful after the initiation of lipid-lowering therapies. Methods: In 25 normolipidemic subjects and 191 treated HL patients (type <, n = 6; IIa, 62; IIb, 66; III, 12; <, 22; and <, 23) from Osaka University Hospital and related hospitals, fasting low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), TG, and apolipoproteins were measured and clinical indices were evaluated statistically. Results: Apo B-48 levels were significantly higher in patients with type <, III, and < HL, and TG levels were significantly higher in patients with type and < HL. The apo B-48/TG ratio was significantly higher only in patients with type III HL compared with other types of HL (p<0.001), and was statistically significant among the other clinical indices (AUC-ROC value, 0.895; cut-off value, 0.110). Conclusion: The apo B-48/TG ratio is a novel and useful marker for detecting type III HL even after the initiation of lipid-lowering interventions.

Original languageEnglish
Pages (from-to)862-871
Number of pages10
JournalJournal of atherosclerosis and thrombosis
Volume19
Issue number9
DOIs
Publication statusPublished - 31-10-2012

Fingerprint

Apolipoprotein B-48
Hypolipidemic Agents
Hyperlipidemias
Triglycerides
Lipids
Screening
Chylomicron Remnants
Apolipoproteins
Apolipoproteins E
LDL Cholesterol
HDL Cholesterol
Lipoproteins
Area Under Curve

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine
  • Biochemistry, medical

Cite this

Yuasa-Kawase, Miyako ; Masuda, Daisaku ; Kitazume-Taneike, Rika ; Yamashita, Taiji ; Kawase, Ryota ; Nakaoka, Hajime ; Inagaki, Miwako ; Nakatani, Kazuhiro ; Tsubakio-Yamamoto, Kazumi ; Ohama, Tohru ; Toyama-Nakagawa, Yumiko ; Nishida, Makoto ; Ishigami, Masato ; Saito, Mieko ; Eto, Masaaki ; Matsuyama, Akifumi ; Komuro, Issei ; Yamashita, Shizuya. / Apolipoprotein B-48 to triglyceride ratio is a novel and useful marker for detection of type III hyperlipidemia after antihyperlipidemic intervention. In: Journal of atherosclerosis and thrombosis. 2012 ; Vol. 19, No. 9. pp. 862-871.
@article{6035b38e9853439c90804117d48942b9,
title = "Apolipoprotein B-48 to triglyceride ratio is a novel and useful marker for detection of type III hyperlipidemia after antihyperlipidemic intervention",
abstract = "Aim: Remnant lipoproteins are atherogenic and are accumulated in patients with type III hyperlipidemia (HL). Although type III HL is diagnosed by phenotyping apolipoprotein (apo) E, this procedure is time-consuming and inconvenient for routine clinical use. Clinical indices for screening type III HL in untreated HL patients have been proposed; however, in clinical settings, HL patients are promptly treated with lipid-lowering agents without diagnosing the underlying cause. We investigated whether existing clinical indices for screening type III HL as well as the apo B-48/triglyceride (TG) ratio, which was suggested to be related to the accumulation of small chylomicron (CM) remnants, are useful after the initiation of lipid-lowering therapies. Methods: In 25 normolipidemic subjects and 191 treated HL patients (type <, n = 6; IIa, 62; IIb, 66; III, 12; <, 22; and <, 23) from Osaka University Hospital and related hospitals, fasting low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), TG, and apolipoproteins were measured and clinical indices were evaluated statistically. Results: Apo B-48 levels were significantly higher in patients with type <, III, and < HL, and TG levels were significantly higher in patients with type and < HL. The apo B-48/TG ratio was significantly higher only in patients with type III HL compared with other types of HL (p<0.001), and was statistically significant among the other clinical indices (AUC-ROC value, 0.895; cut-off value, 0.110). Conclusion: The apo B-48/TG ratio is a novel and useful marker for detecting type III HL even after the initiation of lipid-lowering interventions.",
author = "Miyako Yuasa-Kawase and Daisaku Masuda and Rika Kitazume-Taneike and Taiji Yamashita and Ryota Kawase and Hajime Nakaoka and Miwako Inagaki and Kazuhiro Nakatani and Kazumi Tsubakio-Yamamoto and Tohru Ohama and Yumiko Toyama-Nakagawa and Makoto Nishida and Masato Ishigami and Mieko Saito and Masaaki Eto and Akifumi Matsuyama and Issei Komuro and Shizuya Yamashita",
year = "2012",
month = "10",
day = "31",
doi = "10.5551/jat.13052",
language = "English",
volume = "19",
pages = "862--871",
journal = "Journal of Atherosclerosis and Thrombosis",
issn = "1340-3478",
publisher = "Japan Atherosclerosis Society",
number = "9",

}

Yuasa-Kawase, M, Masuda, D, Kitazume-Taneike, R, Yamashita, T, Kawase, R, Nakaoka, H, Inagaki, M, Nakatani, K, Tsubakio-Yamamoto, K, Ohama, T, Toyama-Nakagawa, Y, Nishida, M, Ishigami, M, Saito, M, Eto, M, Matsuyama, A, Komuro, I & Yamashita, S 2012, 'Apolipoprotein B-48 to triglyceride ratio is a novel and useful marker for detection of type III hyperlipidemia after antihyperlipidemic intervention', Journal of atherosclerosis and thrombosis, vol. 19, no. 9, pp. 862-871. https://doi.org/10.5551/jat.13052

Apolipoprotein B-48 to triglyceride ratio is a novel and useful marker for detection of type III hyperlipidemia after antihyperlipidemic intervention. / Yuasa-Kawase, Miyako; Masuda, Daisaku; Kitazume-Taneike, Rika; Yamashita, Taiji; Kawase, Ryota; Nakaoka, Hajime; Inagaki, Miwako; Nakatani, Kazuhiro; Tsubakio-Yamamoto, Kazumi; Ohama, Tohru; Toyama-Nakagawa, Yumiko; Nishida, Makoto; Ishigami, Masato; Saito, Mieko; Eto, Masaaki; Matsuyama, Akifumi; Komuro, Issei; Yamashita, Shizuya.

In: Journal of atherosclerosis and thrombosis, Vol. 19, No. 9, 31.10.2012, p. 862-871.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Apolipoprotein B-48 to triglyceride ratio is a novel and useful marker for detection of type III hyperlipidemia after antihyperlipidemic intervention

AU - Yuasa-Kawase, Miyako

AU - Masuda, Daisaku

AU - Kitazume-Taneike, Rika

AU - Yamashita, Taiji

AU - Kawase, Ryota

AU - Nakaoka, Hajime

AU - Inagaki, Miwako

AU - Nakatani, Kazuhiro

AU - Tsubakio-Yamamoto, Kazumi

AU - Ohama, Tohru

AU - Toyama-Nakagawa, Yumiko

AU - Nishida, Makoto

AU - Ishigami, Masato

AU - Saito, Mieko

AU - Eto, Masaaki

AU - Matsuyama, Akifumi

AU - Komuro, Issei

AU - Yamashita, Shizuya

PY - 2012/10/31

Y1 - 2012/10/31

N2 - Aim: Remnant lipoproteins are atherogenic and are accumulated in patients with type III hyperlipidemia (HL). Although type III HL is diagnosed by phenotyping apolipoprotein (apo) E, this procedure is time-consuming and inconvenient for routine clinical use. Clinical indices for screening type III HL in untreated HL patients have been proposed; however, in clinical settings, HL patients are promptly treated with lipid-lowering agents without diagnosing the underlying cause. We investigated whether existing clinical indices for screening type III HL as well as the apo B-48/triglyceride (TG) ratio, which was suggested to be related to the accumulation of small chylomicron (CM) remnants, are useful after the initiation of lipid-lowering therapies. Methods: In 25 normolipidemic subjects and 191 treated HL patients (type <, n = 6; IIa, 62; IIb, 66; III, 12; <, 22; and <, 23) from Osaka University Hospital and related hospitals, fasting low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), TG, and apolipoproteins were measured and clinical indices were evaluated statistically. Results: Apo B-48 levels were significantly higher in patients with type <, III, and < HL, and TG levels were significantly higher in patients with type and < HL. The apo B-48/TG ratio was significantly higher only in patients with type III HL compared with other types of HL (p<0.001), and was statistically significant among the other clinical indices (AUC-ROC value, 0.895; cut-off value, 0.110). Conclusion: The apo B-48/TG ratio is a novel and useful marker for detecting type III HL even after the initiation of lipid-lowering interventions.

AB - Aim: Remnant lipoproteins are atherogenic and are accumulated in patients with type III hyperlipidemia (HL). Although type III HL is diagnosed by phenotyping apolipoprotein (apo) E, this procedure is time-consuming and inconvenient for routine clinical use. Clinical indices for screening type III HL in untreated HL patients have been proposed; however, in clinical settings, HL patients are promptly treated with lipid-lowering agents without diagnosing the underlying cause. We investigated whether existing clinical indices for screening type III HL as well as the apo B-48/triglyceride (TG) ratio, which was suggested to be related to the accumulation of small chylomicron (CM) remnants, are useful after the initiation of lipid-lowering therapies. Methods: In 25 normolipidemic subjects and 191 treated HL patients (type <, n = 6; IIa, 62; IIb, 66; III, 12; <, 22; and <, 23) from Osaka University Hospital and related hospitals, fasting low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), TG, and apolipoproteins were measured and clinical indices were evaluated statistically. Results: Apo B-48 levels were significantly higher in patients with type <, III, and < HL, and TG levels were significantly higher in patients with type and < HL. The apo B-48/TG ratio was significantly higher only in patients with type III HL compared with other types of HL (p<0.001), and was statistically significant among the other clinical indices (AUC-ROC value, 0.895; cut-off value, 0.110). Conclusion: The apo B-48/TG ratio is a novel and useful marker for detecting type III HL even after the initiation of lipid-lowering interventions.

UR - http://www.scopus.com/inward/record.url?scp=84867910865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867910865&partnerID=8YFLogxK

U2 - 10.5551/jat.13052

DO - 10.5551/jat.13052

M3 - Article

C2 - 22878701

AN - SCOPUS:84867910865

VL - 19

SP - 862

EP - 871

JO - Journal of Atherosclerosis and Thrombosis

JF - Journal of Atherosclerosis and Thrombosis

SN - 1340-3478

IS - 9

ER -